EUVIMEDEUVIMED entdecken
Open Access

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Veronika Nemethova iD, Petra Babiakova, Boglarka Teglasova, Lucia Uhelska, Andrea Babelova iD, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova und 2 weitere

American Journal of Physiology-Cell Physiology · 2024

DOI: 10.1152/ajpcell.00188.2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Veronika Nemethova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Selecta Biotech SE, Bratislava, Slovakia. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Fusion Proteins, bcr-abl. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Agentúra na Podporu Výskumu a Vývoja (APVV), Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA), Ministerstvo Zdravotnictví Ceské Republiky (MZCR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective treatment modalities targeting leukemic clones that escape tyrosine kinase inhibitor (TKI) therapy could be game changers in the professional management of patients displaying primary resistance, intolerance, or acquired resistance to TKIs. Although delivering authentic innovations today is more complex than ever, we developed a highly potent and safe oligonucleotide-based modality against BCR-ABL1 mRNA named ASP210 that effectively induces cell death in BCR-ABL1-positive TKI-resistant cells while sparing BCR-ABL1-negative healthy cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmProtein Kinase InhibitorsFusion Proteins, bcr-ablOligonucleotidesApoptosisImatinib MesylateHumansCell Line, TumorDasatinibAntineoplastic AgentsCell SurvivalRNA, Messenger

Stichwörter der Autor:innen

BCR-ABL1chronic myelogenous leukemiaoligonucleotide therapeuticsresistance to therapytyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-ablOligonucleotidesImatinib MesylateBCR-ABL1 fusion protein, humanDasatinibAntineoplastic AgentsRNA, Messenger

Autor:innen und Institutionen

  • Selecta Biotech SE, Bratislava, Slovakia.
  • Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  • Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.

ORCID-Profile: Veronika Nemethova, Andrea Babelova

Förderung

  • Agentúra na Podporu Výskumu a Vývoja (APVV)
  • Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA)
  • Ministerstvo Zdravotnictví Ceské Republiky (MZCR)
  • Slovenská Akadémia Vied (SAV)

Zitieren

APA

Nemethova, V., Babiakova, P., Teglasova, B., Uhelska, L., Babelova, A., Selc, M., Jakic, K., Mitrovsky, O., Myslivcova, D., Zackova, M., Poturnayova, A., Batorova, A., Drgona, L., & Razga, F. (2024). ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00188.2024

Vancouver

Nemethova V, Babiakova P, Teglasova B, Uhelska L, Babelova A, Selc M, et al. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00188.2024

BibTeX
@article{Nemethova2024,
  author = {Nemethova, Veronika and Babiakova, Petra and Teglasova, Boglarka and Uhelska, Lucia and Babelova, Andrea and Selc, Michal and Jakic, Kristina and Mitrovsky, Ondrej and Myslivcova, Denisa and Zackova, Marketa and Poturnayova, Alexandra and Batorova, Angelika and Drgona, Lubos and Razga, Filip},
  title = {ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2024},
  doi = {10.1152/ajpcell.00188.2024}
}
Kostenlos starten →